These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22033940)

  • 1. CML: live long and prosper.
    Larson RA
    Blood; 2011 Oct; 118(17):4499-500. PubMed ID: 22033940
    [No Abstract]   [Full Text] [Related]  

  • 2. Elderly CML patients' treatment: considering not only physician's judgment but also co-morbidity indexes.
    Sánchez-Guijo F
    Leuk Res; 2014 Oct; 38(10):1156-7. PubMed ID: 25113280
    [No Abstract]   [Full Text] [Related]  

  • 3. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Gleevec--the next generation in CML.
    Fricker J
    Eur J Cancer; 2006 Feb; 42(3):275. PubMed ID: 16514710
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
    Efficace F; Baccarani M; Breccia M; Alimena G; Rosti G; Cottone F; Deliliers GL; Baratè C; Rossi AR; Fioritoni G; Luciano L; Turri D; Martino B; Di Raimondo F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Ulisciani S; Veneri D; Sica S; Rambaldi A; Vignetti M; Mandelli F;
    Blood; 2011 Oct; 118(17):4554-60. PubMed ID: 21750313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which TKI should be recommended as initial treatment for CML in chronic phase?
    Schiffer CA
    Oncology (Williston Park); 2012 Oct; 26(10):912, 914. PubMed ID: 23175997
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of chronic myelogenous leukemia by using imatinib].
    Jinnai I
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
    [No Abstract]   [Full Text] [Related]  

  • 9. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
    Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
    Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
    Holtz MS; Bhatia R
    Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 12. Front-line TKI therapy for chronic-phase CML: the luxury of choice.
    Shah NP
    Oncology (Williston Park); 2012 Oct; 26(10):908, 910, 912. PubMed ID: 23175996
    [No Abstract]   [Full Text] [Related]  

  • 13. Dasatinib is effective in imatinib-resistant CML.
    Cannell E
    Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G; Cortes JE
    Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.
    Soderquist C; Bagg A
    Blood; 2014 Oct; 124(15):2463. PubMed ID: 25436260
    [No Abstract]   [Full Text] [Related]  

  • 17. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 18. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
    Yeung DT; White DL
    Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.